Abstract
Despite the wide use of immunotherapy in the treatment of solid tumours, it is effective only in 20 - 40 % of patients according to histopathological type. The aim of our project is to predict response to immunotherapy based on a comprehensive analysis of the tumour, its microenvironment, and the host. To date, we have prospectively enrolled 70 patients with advanced or metastatic solid tumours who were treated with anti-PD-1 / anti-PDL-1 antibodies. Here we present preliminary results from a subanalysis of 23 patients with NSCLC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
